The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
Take time out with a 30-minute soundscape of classical gems.
Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...
On World Cancer Day, Mamta Mohandas, Yuvraj Singh, Lisa Ray, and others inspire with their cancer survival stories.
Belfast Live on MSN11d
'I was in a state of shock' - NI woman told she didn't have cancer - months before stage 4 diagnosisUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback